Skip to content

King’s College Hospital begins enrolling patients with Type 1 diabetes for new study

13 August 2024 - King’s College Hospital begins enrolling patients with Type 1 diabetes for new study

King’s College Hospital, along with Guy’s and St Thomas’ hospitals, are currently enrolling adult patients for ongoing clinical studies evaluating multiple investigational therapies that may target the inability to produce insulin in people with type 1 diabetes.

The therapies are ‘investigational’ meaning that they are not approved for use by any regulatory agencies in Europe, the United Kingdom, the United States, or elsewhere. The aim of these studies is to evaluate if the investigational therapies could potentially improve blood glucose control and reduce the need to take insulin in individuals with T1D.

FORWARD Study

The FORWARD Study is evaluating the safety and efficacy of an investigational islet cell infusion in individuals with type 1 diabetes and severe low blood sugar (hypoglycaemia). These individuals have experienced hypoglycaemic events, meaning they have required assistance from someone else to recover from low blood sugar. The investigational therapy is delivered by an infusion into the liver and requires the use of immunosuppressive medications to protect the islet cells from the immune system.

To generally qualify for the study individuals must meet the following key criteria:

  • Be between the ages of 18 and 65 (inclusive)
  • Have had T1D for at least five years
  • Experienced at least two episodes of severe hypoglycaemia in the past year
  • Be willing to use continuous glucose monitoring for the duration of the study

Patients will not qualify for the FORWARD Study if they have had prior islet cell therapy, organ transplant, or cell therapy; or advanced complications associated with diabetes. There are additional eligibility requirements, which the study doctor will discuss with those interested in participating.

For more information on these clinical studies, please visit mytomorro.ws/t1d-upward-enuk or mytomorro.ws/forward-enuk or contact:

Dr Sufyan Hussain (PI) and research team via email [email protected]

These studies have been approved by the Health Research Authority (REC reference 22/LO/0839, IRAS ID 1006463).